We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros Platform Integrated into Second, US-Based, Contract Research Organization
News

Gyros Platform Integrated into Second, US-Based, Contract Research Organization

Gyros Platform Integrated into Second, US-Based, Contract Research Organization
News

Gyros Platform Integrated into Second, US-Based, Contract Research Organization

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros Platform Integrated into Second, US-Based, Contract Research Organization"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gyros AB confirmed that Radix BioSolutions, a US-based contract research organization specializing in custom assay development, reagent manufacturing, and a provider of assay services, will integrate a Gyrolab™ xP workstation into their immunoassay development programs.

Kerry Oliver, CEO at Radix Biosolutions explained the reasoning behind the decision, “The Gyros™ platform enables us to develop immunoassays more rapidly than any other approaches currently available. At Radix we differentiate ourselves by fostering strong relationships with our customers by meeting project requirements and timelines, and always striving to exceed expectations. Our scientists provide the experience and capabilities in reagent definition and production, robust assay development and validation, and the regulatory compliance required during the development of a customer’s therapeutic. It is essential for us to leverage leading edge technology at each stage of a project in order to best fulfill the unique needs of each customer.”

Erik Wallden, CEO at Gyros, added: “We are extremely pleased that Radix BioSolutions have recognized one of the key benefits of our immunoassay platform, namely rapid assay development. We also believe that their unique approach of making identified assay reagents commercially available will enable other Gyrolab xP workstation users working in GLP environments in the USA to procure quality controlled reagents from Radix for their own laboratory needs.”
Advertisement